Sensei Bio stock skyrockets on acquisition and $200m financing Sensei stock surges after acquiring Faeth Therapeutics and securing $200 million private placement to advance cancer pipeline.

Sensei Biotherapeutics stock skyrockets 206% after acquiring Faeth Therapeutics and securing $200M private placement. The deal advances PIKTOR, a promising PI3K/mTOR inhibitor for endometrial and breast cancer.
#News #SenseiBio #Biotech #CancerResearch #StockNews #PIKTOR

Sensei Bio stock skyrockets on acquisition and $200m financing Sensei stock surges after acquiring Faeth Therapeutics and securing $200 million private placement to advance cancer pipeline.

Sensei Biotherapeutics stock skyrockets 206% after acquiring Faeth Therapeutics and securing $200M private placement. The deal advances PIKTOR, a promising PI3K/mTOR inhibitor for endometrial and breast cancer.
#News #SenseiBio #Biotech #CancerResearch #StockNews #PIKTOR

@biorasi.bsky.social Chris O'Brien welcomes John Celebi, President and CEO at #senseibio, to the latest episode of the Few & Far Between podcast.

Tune in today! Find this new episode on your favorite streaming platform or visit >> lnkd.in/g2KE2SGA #Biorasi2025

youtube.com/shorts/zjDh3...

Tune in tomorrow for a new episode of @biorasi.bsky.social Few & Far Between. Host Chris O'Brien welcomes John Celebi, CEO at #senseibio, to the podcast to discuss the importance of building a framework for teamwork, leadership, and culture in today's biotechs. #YourGoToCRO #clinicaltrial